Cargando…

Association between IDO activity and prognosis in patients with non-small cell lung cancer after radiotherapy

BACKGROUND: Indoleamine 2,3-dioxygenase (IDO), a limiting enzyme in the IDO/kynurenine (Kyn) pathway, converts tryptophan (Trp) into Kyn, and plays a significant role in immune suppression and tumor immune evasion. This study aimed to investigate the association between IDO activity and clinical out...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yaoyao, Jiang, Chenxue, Liu, Yuanjun, Li, Yefei, Wu, He, Feng, Jianguo, Xu, Yaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576049/ https://www.ncbi.nlm.nih.gov/pubmed/33241018 http://dx.doi.org/10.21037/atm-20-5634

Ejemplares similares

The association between the ERCC1/2 polymorphisms and radiotherapy efficacy in 87 patients with non-small cell lung cancer
por: Jiang, Chenxue, et al.
Publicado: (2021)

Stereotactic body radiotherapy for early stage non-small cell lung cancer in patients with subclinical interstitial lung disease
por: Liu, Yuanjun, et al.
Publicado: (2020)

High PD-L1 expression is associated with a favorable prognosis in patients with esophageal squamous cell carcinoma undergoing postoperative adjuvant radiotherapy
por: Jiang, Chenxue, et al.
Publicado: (2019)

A retrospective study of shrinking field radiation therapy during chemoradiotherapy in stage III non-small cell lung cancer
por: Jiang, Chenxue, et al.
Publicado: (2018)

A Propensity-Matched Analysis of Survival of Clinically Diagnosed Early-Stage Lung Cancer and Biopsy-Proven Early-Stage Non-Small Cell Lung Cancer Following Stereotactic Ablative Radiotherapy
por: Zhang, Ran, et al.
Publicado: (2021)

Four-year follow-up outcomes after stereotactic body radiation therapy for central early-stage non-small cell lung cancer
por: Sun, Xiaojiang, et al.
Publicado: (2020)

Effect of Adjuvant Magnetic Fields in Radiotherapy on Non-Small-Cell Lung Cancer Cells In Vitro
por: Feng, Jianguo, et al.
Publicado: (2013)

Correlation of neuroendocrine features with prognosis of non-small cell lung cancer
por: Feng, Jianguo, et al.
Publicado: (2016)

Five-year follow-up after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer: a multicenter study
por: Guo, Yanling, et al.
Publicado: (2023)

Increased Expression of TAP Is Predictive of Poor Prognosis in Patients with Non-Small Cell Lung Cancer
por: Cheng, Yuanjun, et al.
Publicado: (2020)

Palliative thoracic radiotherapy dose, non-small cell lung cancer with oligometastases and prognosis
por: Ampil, Federico L., et al.
Publicado: (2011)

Radiosensitizing effect of c-Met kinase inhibitor BPI-9016M in esophageal squamous cell carcinoma cells in vitro and in vivo
por: Jiang, Chenxue, et al.
Publicado: (2021)

High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
por: Ludovini, Vienna, et al.
Publicado: (2021)

Glycolytic Genes Predict Immune Status and Prognosis Non-Small-Cell Lung Cancer Patients with Radiotherapy and Chemotherapy
por: Zhao, Tianye, et al.
Publicado: (2023)

Precision radiotherapy for non-small cell lung cancer
por: Yang, Wen-Chi, et al.
Publicado: (2020)

Radiotherapy for oligometastatic tumor improved the prognosis of patients with non‐small cell lung cancer (NSCLC)
por: Gong, Hong‐yun, et al.
Publicado: (2019)

Effects of LncRNA MEG3 on immunity and autophagy of non-small cell lung carcinoma through IDO signaling pathway
por: Wang, Chuanqiang, et al.
Publicado: (2021)

IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2014)

Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
por: Zhang, Luping, et al.
Publicado: (2016)

Impact of IDO1 and IDO2 on the B Cell Immune Response
por: Merlo, Lauren M. F., et al.
Publicado: (2022)

Increased effect of two-fraction radiotherapy in conjunction with IDO1 inhibition in experimental glioblastoma
por: Ahlstedt, Jonatan, et al.
Publicado: (2020)

Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study
por: Jing, Wang, et al.
Publicado: (2021)

The CT appearance pattern of radiation-induced lung injury and tumor recurrence after stereotactic body radiation therapy in early stage non-small cell lung cancer
por: Li, Qian, et al.
Publicado: (2020)

Correction: IDO1 and IDO2 Non-Synonymous Gene Variants: Correlation with Crohn's Disease Risk and Clinical Phenotype
por: Lee, Alexander, et al.
Publicado: (2015)

Immune Response on Optimal Timing and Fractionation Dose for Hypofractionated Radiotherapy in Non–Small-Cell Lung Cancer
por: Zhao, Xianlan, et al.
Publicado: (2022)

Dual inhibition of IDO1/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer
por: Wu, Chunjing, et al.
Publicado: (2023)

IDO1 Expression Increased After Neoadjuvant Therapy Predicts Poor Pathologic Response and Prognosis in Esophageal Squamous Cell Carcinoma
por: Jiao, Ruidi, et al.
Publicado: (2020)

On the Non-Redundant Roles of TDO2 and IDO1
por: Puccetti, Paolo
Publicado: (2014)

A Mathematical Model of Cancer Treatment by Radiotherapy
por: Liu, Zijian, et al.
Publicado: (2014)

International consensus on radiotherapy in metastatic non-small cell lung cancer
por: Zhu, Zhengfei, et al.
Publicado: (2022)

T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer
por: Wu, Lirong, et al.
Publicado: (2021)

Combined radiotherapy and immunotherapy using CPG oligodeoxynucleotides and indolamine 2,3 dioxygenase (IDO) blockade
por: Monjazeb, Arta M, et al.
Publicado: (2013)

Automated Information Extraction on Treatment and Prognosis for Non–Small Cell Lung Cancer Radiotherapy Patients: Clinical Study
por: Zheng, Shuai, et al.
Publicado: (2018)

High indoleamine-2,3-dioxygenase 1 (IDO) activity is linked to primary resistance to immunotherapy in non-small cell lung cancer (NSCLC)
por: Kocher, Florian, et al.
Publicado: (2021)

Differential Roles of IDO1 and IDO2 in T and B Cell Inflammatory Immune Responses
por: Merlo, Lauren M. F., et al.
Publicado: (2020)

Prognosis of non-small cell lung cancer patients with bone oligometastases treated concurrently with thoracic three-dimensional radiotherapy and chemotherapy
por: Ouyang, Wei-Wei, et al.
Publicado: (2014)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy
por: JIA, HEJIN, et al.
Publicado: (2016)

Activities of plasma indoleamine-2, 3-dioxygenase (IDO) enzyme in Nigerian patients with lung diseases: basis for tryptophan supplementation or IDO inhibitor use
por: Arinola, Ganiyu Olatunbosun, et al.
Publicado: (2023)

Impact of anesthetic factors on prognosis of patients with non-small cell lung cancer after surgery
por: Zhu, Wenzhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hlse2fsg2pnraqfkpfu46ht1q1